目的 探討七蕊胃舒膠囊聯(lián)合蘭索拉唑腸溶膠囊治療慢性淺表性胃炎的臨床療效。方法 選取2023年6月—2024年6月在上海交通大學(xué)醫(yī)學(xué)院附屬第六人民醫(yī)院確診并規(guī)范治療的100例慢性淺表性胃炎患者作為研究對(duì)象，按照確診入組的時(shí)間順序?qū)⑵浞譃閷?duì)照組和治療組，每組各有50例。對(duì)照組患者采用蘭索拉唑腸溶膠囊口服治療，1次30 mg，1日1次。治療組患者在對(duì)照組治療基礎(chǔ)上加用七蕊胃舒膠囊口服治療，1次4粒，1日2次，于早晚飯前0.5 h服用。兩組患者均接受了為期4周的連續(xù)治療。觀察兩組患者的臨床療效，比較兩組治療前后中醫(yī)證候評(píng)分、慢性病患者生命質(zhì)量測(cè)定量表（QLICD-CG）評(píng)分、血清胃泌素（GAS）、胃蛋白酶原Ⅰ（PGI）及胃泌素17（G-17）水平的變化情況。結(jié)果 規(guī)律治療后，治療組和對(duì)照組總有效率分別為96.00%、84.00%，組間比較有顯著性差異（P＜0.05）。治療后，兩組患者中醫(yī)證候評(píng)分均較治療前顯著下降，而QLICD-CG評(píng)分均較治療前顯著升高（P＜0.05）；相關(guān)評(píng)分方面治療組患者明顯優(yōu)于對(duì)照組（P＜0.05）。治療后，兩組患者血清GAS、G-17水平均顯著降低，而PGI水平則顯著提升（P＜0.05）；治療后，治療組患者GAS、G-17水平低于對(duì)照組，PGI水平高于對(duì)照組（P＜0.05）。結(jié)論 七蕊胃舒膠囊聯(lián)合蘭索拉唑治療慢性淺表性胃炎療效顯著，可有效減輕患者臨床癥狀，提升生活質(zhì)量，同時(shí)促進(jìn)血清學(xué)相關(guān)指標(biāo)的恢復(fù)，具備廣泛的臨床應(yīng)用前景。

Objective To investigate the therapeutic effect of Qirui Weishu Capsules combined with lansoprazole in treatment of chronic superficial gastritis. Methods A total of 100 patients with chronic superficial gastritis diagnosed and treated in the Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from June 2023 to June 2024 were selected as the study objects, and were divided into control group and treatment group according to the chronological order of diagnosis and inclusion, with 50 cases in each group. Patients in control group were po administered with Lansoprazole Enteric Capsules, 30 mg/time, once daily. Patients in treatment group were po administered with Qirui Weishu Capsules on basis of control group, 4 capsules/time, twice daily, half an hour before morning and evening meals. Both groups received continuous treatment for 4 weeks. The clinical efficacy of the two groups was observed, and the changes of TCM syndrome score, QLICD-CG score, GAS, PGI, and G-17 levels before and after treatment were compared between two groups. Results After regular treatment, the total effective rate of treatment group and control group was 96.00% and 84.00%, respectively, with significant difference between groups (P < 0.05). After treatment, TCM syndrome scores in both groups were significantly decreased, but QLICD-CG scores were significantly increased compared with before treatment (P < 0.05). The scores in treatment group were significantly better than those in control group (P < 0.05). After treatment, serum GAS and G-17 levels were significantly decreased, but PGI levels were significantly increased in two groups (P < 0.05). After treatment, GAS and G-17 levels in treatment group were lower than those in control group, but PGI levels were higher than those in control group (P < 0.05). Conclusion Qirui Weishu Capsules combined with lansoprazole is effective in treatment of chronic superficial gastritis, and can effectively reduce the clinical symptoms of patients, improve the life quality, and promote the recovery of serological related indicators, which has a wide range of clinical application prospects.

R975

國(guó)家自然科學(xué)基金資助項(xiàng)目（82074063）